Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExpMACs: Expanded Access to CD3+/CD19+ Depleted Stem Cells
NCT02356653Phase 1Recruiting
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Dec 2013
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in leukemia, Inborn errors of metabolism (IEM), bone marrow failure syndrome (BMFS) and 5 more, sponsored by Children's Hospital of Philadelphia. Primary endpoint: Overall Survival at 1 year. Started Dec 2013; status: recruiting.
02
Conditions
leukemiaInborn errors of metabolism (IEM)bone marrow failure syndrome (BMFS)immunodeficiencyImmunodysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome (IPEX)
Beyond the preview
Go deeper on NCT02356653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02356653.